- Home
- MDWD vs GSHR Comparison
MDWD vs GSHR Comparison
Compare MDWD & GSHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- GSHR
- Stock Information
- Founded
- MDWD 2000
- GSHR 2024
- Country
- MDWD Israel
- GSHR United States
- Employees
- MDWD N/A
- GSHR N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- GSHR
- Sector
- MDWD Health Care
- GSHR
- Exchange
- MDWD Nasdaq
- GSHR NYSE
- Market Cap
- MDWD 208.2M
- GSHR 205.8M
- IPO Year
- MDWD 2014
- GSHR 2025
- Fundamental
- Price
- MDWD $20.13
- GSHR $10.13
- Analyst Decision
- MDWD Strong Buy
- GSHR
- Analyst Count
- MDWD 2
- GSHR 0
- Target Price
- MDWD $35.00
- GSHR N/A
- AVG Volume (30 Days)
- MDWD 58.5K
- GSHR 294.0
- Earning Date
- MDWD 08-13-2025
- GSHR 01-01-0001
- Dividend Yield
- MDWD N/A
- GSHR N/A
- EPS Growth
- MDWD N/A
- GSHR N/A
- EPS
- MDWD N/A
- GSHR N/A
- Revenue
- MDWD $19,213,000.00
- GSHR N/A
- Revenue This Year
- MDWD $20.64
- GSHR N/A
- Revenue Next Year
- MDWD $25.71
- GSHR N/A
- P/E Ratio
- MDWD N/A
- GSHR N/A
- Revenue Growth
- MDWD N/A
- GSHR N/A
- 52 Week Low
- MDWD $14.14
- GSHR $9.97
- 52 Week High
- MDWD $22.51
- GSHR $10.50
- Technical
- Relative Strength Index (RSI)
- MDWD 53.36
- GSHR N/A
- Support Level
- MDWD $19.73
- GSHR N/A
- Resistance Level
- MDWD $20.97
- GSHR N/A
- Average True Range (ATR)
- MDWD 0.71
- GSHR 0.00
- MACD
- MDWD 0.06
- GSHR 0.00
- Stochastic Oscillator
- MDWD 57.08
- GSHR 0.00
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About GSHR GESHER ACQUISITION CORPORATION II ORD USD0.0001 CL A
Gesher Acquisition Corp II is a blank check company.